Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2012 Scrip 100 Preview: Base jumping for pharma – a slower descent from the patent cliff?

This article was originally published in Scrip

Executive Summary

If there is one fact that even the most casual observer of the pharma industry is aware of, it is that there is a patent cliff, and many companies in the process of falling off it! The latest numbers suggest that brands generating more than $150 billion in global sales in 2010 will lose primary patent protection in at least one major market by 2015.

You may also be interested in...



2012 Scrip 100: How to get more 'wag' from the tail – managing mature brands in immature markets

In the good old days of pharma, when pipelines were plentiful, Western markets were a haven for strong prices and double digit growth was a given, little thought or focus was given to those teams working with mature brands or those trying to get difficult 'emerging' markets on the radar.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel